Computerized cognitive testing in patients with type I Gaucher disease: Effects of enzyme replacement and substrate reduction
- 1 February 2005
- journal article
- clinical trial
- Published by Elsevier in Genetics in Medicine
- Vol. 7 (2) , 124-130
- https://doi.org/10.1097/01.gim.0000153666.23707.ba
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- The role of the iminosugar N‐butyldeoxynojirimycin (miglustat) in the management of type I (non‐neuronopathic) Gaucher disease: A position statementJournal of Inherited Metabolic Disease, 2003
- Substrate reduction therapy: miglustat as a remedy for symptomatic patients with Gaucher disease type 1Expert Opinion on Investigational Drugs, 2003
- Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher RegistryThe American Journal of Medicine, 2002
- Low-Dose N-Butyldeoxynojirimycin (OGT 918) for Type I Gaucher DiseaseBlood Cells, Molecules, and Diseases, 2002
- Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesisThe Lancet, 2000
- Treatment of Gaucher disease with an enzyme inhibitorGlycoconjugate Journal, 1996
- Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's DiseaseNew England Journal of Medicine, 1991
- Prediction of verbal, performance, and full scale IQs from seven subtests of the wais-rJournal of Clinical Psychology, 1990
- Determinants of performance on the Rey‐Osterrieth Complex Figure Test: An analysis, and a new technique for single‐case assessmentBritish Journal of Clinical Psychology, 1984
- “Mini-mental state”Journal of Psychiatric Research, 1975